Before add-on therapy, the urine output rate increases, voided volume at each voiding also increases in normal subjects. This is generally understood as the VARD. The association between the urine output rate and voided volume at each voiding was analyzed in each group. P-values <0.05 were considered significant.

After add-on therapy, there was a significant association between the urine output rate and voided volume. After add-on therapy, the urine output rate and each voided volume remained correlated. These results suggest that the add-on therapy ameliorates residual OAB symptoms of male LUTS patients by improving the VARD.

Interpretation of Result

The lack of VARD may contribute to maintaining OAB symptoms of male LUTS patients despite treatment with ABs or 5ARIs. The VARD may be a useful predictor of the efficacy of add-on therapy for OAB symptoms in men treated for LUTS.

Limitation

This study is a retrospective and small group study, thus it requires a prospective approach to more patients.

Conclusions

These results suggest that the add-on therapy ameliorates residual OAB symptoms of male LUTS patients by improving the VARD.

References


#83 Diuretic adaptation as a predictor of the add-on therapy for overactive bladder symptoms in men treated for low urinary tract symptoms

Kanako Matsuoka 1,2, Hidenori Aikahata 1, Akifumi Onagi 1, Ryo Tanji 1, Ruriko Honda 1, Seiji Hoshi 1, Tomoyuki Koguchi 1, Junya Hata 1, Yuichi Sato 1, Masao Kataoka 1, Soichiro Ogawa 1, Nobuhiro Hagai 1, Fusao Murakami 1, Kei Ishibashi 1, Ken Akawa 1, Yoshiyuki Kojima 1

1. Department of Urology, Fukushima Medical University School of Medicine, Fukushima, Japan.
2. Department of Urology, Ohta Nishinouchi Hospital, Koriyama, Japan.

The vesical adaptation response to diuresis (VARD)

When urine output rate increases, voided volume at each voiding also increases in normal subjects. This is generally understood as the VARD.

Urine output rate

100 ml/hr

200 ml/hr

300 ml

500 ml

Functional Bladder Capacity

The bladder adapts to diuresis.

Introduction

Recently, attention has focused on VARD. It has been indicated that the VARD is lacking in overactive bladder (OAB). On the other hand, male lower urinary tract symptoms (male LUTS) secondary to bladder outlet obstruction (BOO) are common and interfere with the quality of life (QOL) of elderly men. Current oral therapies for male LUTS recommended by guidelines include α-adrenoceptor antagonists (α-blockers, Abs) and 5α-reductase inhibitors (5ARIs). Some studies reported that AB and/or 5ARI monotherapy did not improve OAB symptoms of male LUTS patients sufficiently. It was suggested that muscarinic receptor antagonists (MRAs) or β3-adrenoceptor (β3-AR) agonist add-on therapy to the drug was effective for some patients with residual OAB symptoms. However, useful predictors of add-on therapy improving OAB symptoms in male LUTS patients remain unclear. The aim of this study was to determine whether the VARD can be used to predict the efficacy of add-on therapy for OAB symptoms in men treated for LUTS.

Aim of Study

Men with LUTS who had residual OAB symptoms despite treatment with ABs or 5ARIs for one year and received add-on therapy (MRAs or β3-AR agonist) were included in this study. OAB was evaluated using the Overactive Bladder Symptom Score (OABSS). Residual OAB was defined as an OABSS total score greater than 3 and an urgency score greater than 2 before add-on therapy. Uroflowmetry, ultrasonography to measure the prostate volume, and 24-h frequency-volume charts (FVCs) were evaluated before and after add-on therapy.

Statistical analysis

The association between the urine output rate and voided volume at each voiding was analyzed in each group. P-values <0.05 were considered significant.

Study design

Patients and methods

Men with LUTS who had residual OAB symptoms despite treatment with ABs or 5ARIs for one year and received add-on therapy (MRAs or β3-AR agonist) were included in this study. OAB was evaluated using the Overactive Bladder Symptom Score (OABSS). Residual OAB was defined as an OABSS total score greater than 3 and an urgency score greater than 2 before add-on therapy. Uroflowmetry, ultrasonography to measure the prostate volume, and 24-h frequency-volume charts (FVCs) were evaluated before and after add-on therapy.

Method of determining VARD

The 24-h frequency-volume chart (FVC) recorded the degree of urgency, as well as the volumes voided and the time of each micturition. The urine output rate was calculated by dividing the volume voided by the interval between 2 successive micturitions. Since the functional bladder capacity at night was demonstrated to be different from the daytime capacity, we use daily urination only.

References


Disclosures Statement: Self funded.